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REVIEW
Abstract: The association between malignancy and venous thromboembolic disease has
been recognized for over a century and a half. During this time, a substantial body of literature
has developed showing that malignancy is not only a hypercoagulable state characterized by
an increased risk of thrombosis but also that components of blood coagulation reactions are
capable of supporting tumor growth and dissemination. In recent years a succession of
meticulously performed clinical trials has clarified optimal therapy intended to both prevent
and treat thromboembolism that occurs in the setting of cancer. However, much remains to be
accomplished in terms of practitioner education on the merits of optimal therapy. Of perhaps
greater interest is the possibility that drugs capable of controlling cancer-associated
hypercoagulability may provide a means for improving cancer survival while avoiding the
toxicities characteristic of conventional anti-tumor therapy. Clearly, ample incentive exists
for collaboration between basic and clinical scientists interested in improving the management
of malignancy and its thromboembolic complications.
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Introduction
Venous thromboembolism (VTE) is a major problem in cancer patients that
significantly and negatively affects both morbidity and mortality (Heit et al 1999;
Lip et al 2002; Khorana 2003). Cancer and VTE have a two-way clinical correlation.
For example, the presence of malignant or pre-malignant cells may trigger systemic
coagulation activation that leads to VTE while an activated coagulation mechanism
may impact malignant progression. Thromboembolism may be recognized at the
time of first cancer diagnosis, may complicate the course of established malignancy
or may occur well before the first recognition of cancer (Hettiarachchi et al 1998;
Zacharski 2003; Monreal et al 2004). In this review, we will discuss the occurrence
and clinical significance of cancer-associated VTE, the prophylaxis and treatment of
VTE in cancer patients, and the potential anticancer effects of low molecular weight
heparins.
Thromboembolism in cancer patients
Prevalence and clinical significance of venous
thromboembolism in cancer patients
VTE is common in cancer patients. Of all patients presenting with acute VTE, 15%
to 20% are associated clinically with malignancy; 2%–5% of these are diagnosed
concurrently with cancer, and 5%–10% are diagnosed with cancer during follow-up.
Clearly, cancer patients are at a higher risk of VTE than are patients without cancer.
Levitan and colleagues (1999) examined the association between the diagnosis of
cancer and the occurrence of VTE and showed that VTE was significantly more
common in patients with versus without malignancy at the time of first hospitalization.
Furthermore, the risk of readmission with recurrent VTE as well as death within 6
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months was significantly greater in patients with
malignancy-associated VTE compared with VTE without
malignancy. Some data are available regarding the incidence
of VTE among patients with specific types of cancer (Chew
et al 2006). The Medicare database showed highest
cumulative incidence of VTE in patients with cancer of the
ovary, brain, pancreas, and lymphoma followed by cancer
of the gastrointestinal tract, leukemia, and lung (Levitan et
al 1999). Analysis of large databases has indicated that
cancer patients who either develop a VTE during the course
of established cancer or are diagnosed with a thrombotic
episode when cancer is first diagnosed have poorer survival
compared with cancer patients without thrombosis
(Sorensen et al 2000; Alcalay et al 2006)
Active cancer is associated with a hypercoagulable state
that is attributable to the interaction of multiple mechanisms.
Examples of such interacting mechanisms include venous
stasis due to immobilization that commonly accompanies
the poor performance status characteristic of malignancy,
recent cancer surgery, release of procoagulant factors
produced by the tumor cells or activated host macrophages,
endothelial damage caused by central vein catheters,
radiotherapy, chemotherapy or hormonal therapy. The
complexity of this process is illustrated by the fact that
alteration in several of these contributing factors together
with activation of components of hemostatic pathways is
likely to contribute to thrombosis in individual cancer
patients (Lee and Levine 2002).
The strength and clinical importance of the association
between cancer and thrombosis has led to several trials
exploring the benefits of pharmacologic thrombo-




thromboprophylaxis in cancer patients
undergoing surgery
The risk of postoperative VTE is approximately twice as
high in cancer patients as in patients undergoing comparable
surgery for benign conditions (Clagett and Reisch 1988).
The increased risk of VTE in cancer patients undergoing
surgery is comparable with that in other high-risk surgical
procedures such as orthopedic surgery. Investigation into
the optimal dose of low molecular weight heparin (LMWH)
for prophylaxis during cancer surgery has shown that a “high
prophylactic” dose of dalteparin, 5000 IU, administered once
daily for 7 days is significantly more effective than 2500 IU,
and is equally safe (Bergqvist et al 1995). Mismetti and
colleagues (2001) have conducted a meta-analysis of trials
that compared LMWH with unfractionated heparin (UFH)
in high risk surgery and the results of these trials provide
evidence that once daily LMWH is as safe and effective as
multiple injections of UFH per day for the prophylaxis of
postoperative DVT in patients with cancer.
In patients undergoing abdominal surgery, increased
levels of D-dimer have been shown to persist for at least 14
days, with levels being significantly higher in cancer patients
compared with patients without cancer (Galster et al 2000).
The extended activation of the coagulation system in cancer
suggests that patients undergoing major abdominal surgery
are a particularly high-risk population who may benefit from
prolonged thromboprophylaxis. Given the concept that the
risk of VTE extends beyond the immediate postoperative
period in patients undergoing cancer surgery, the Duration
of Prophylaxis against Venous Thromboembolism with
Enoxaparin After Surgery for Cancer (ENOXACAN II)
investigators studied extended prophylaxis in cancer surgery
(Bergqvist et al 2002). In this randomized, double-blind trial,
patients undergoing surgery for abdominal malignancy
received one week of enoxaparin and then were randomly
assigned to enoxaparin or placebo for 21 more days. The
incidence of late occurring VTE assessed by bilateral
venography was 12% with placebo compared with 4.8% in
the prolonged thromboprophylaxis group, a 60% relative
risk reduction. These results are supported by data from a
trial conducted by Rasmussen and colleagues (2003) This
prospective, randomized multicenter clinical trial, FAME
(prolonged thromboprophylaxis with Fragmin After Major
Surgery), was designed to evaluate the efficacy and safety
of 1 week compared with 4 weeks of thromboprophylaxis
with dalteparin following major abdominal surgery. A
subgroup analysis of 198 cancer patients entered in this study
showed that extending thromboprophylaxis from 1 week to
4 weeks reduced significantly the incidence of
venographically proven DVT from 19.6% to 8.8% and also
reduced the incidence of proximal DVT. In both studies,
the risk of bleeding was not increased with prolonged
prophylaxis. These two studies support the use of extended
thromboprophylaxis with LMWH after major surgery for
malignant disease to reduce the risk of VTE. However, to
develop more secure evidence-based treatment guidelines,
more research is required to show that further extension of
anticoagulant treatment beyond hospitalization will decrease
VTE risk to an even greater extent.Vascular Health and Risk Management 2006:2(4) 353
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Prophylaxis in medical patients with
cancer
The ability to identify medical patients with cancer at
greatest risk for thrombosis would facilitate more effective
use of thromboprophylaxis. There are two main clinical
settings that physicians should consider. The first involves
the ambulatory patient who is receiving chemotherapy or
radiotherapy, and the second is the cancer patient that is
bedridden for an extended period of time. Interestingly, the
Fundamental
 Research in Oncology and Thrombosis
(FRONTLINE) survey showed that cancer patients under
medical management do not commonly receive
thromboprophylaxis (Wolff 2003). In such cancer patients,
the cause of this risk and the timing of risk assessment are
indistinct because risk factors are multiple and ever
changing. For example, the incidence of thrombosis is
increased with chemotherapy and hormonal therapy, and
also with newer targeted anti-cancer agents such as anti-
angiogenic and cytokine therapy. For example, in breast
cancer, both tamoxifen and cytotoxic chemotherapy appear
to increase the risk for VTE independently. In a review of
2673 breast cancer patients in trials organized by the Eastern
Cooperative Oncology Group, venous and arterial
thromboses were significantly more common among women
receiving chemotherapy plus hormonal therapy than in
controls (Saphner et al 1991). In a double blind clinical trial,
311 patients with metastatic breast cancer were randomized
to receive either very low dose warfarin (international
normalized ratio [INR] of 1.3 to 1.9) or placebo while they
were receiving chemotherapy (Levine et al 1994). This study
showed an 85% relative reduction in risk of thrombosis in
patients randomized to receive warfarin (p=0.031) with no
increase in risk of bleeding complications.
Prophylaxis for central vein catheter
thrombosis
Central venous catheters (CVC) are used commonly for the
administration of chemotherapeutic agents, blood
components, or parenteral nutrition in cancer patients. The
incidence of catheter-associated VTE reported in studies
enrolling cancer patients is highly variable ranging from as
low as 4% to as high as 66% (Balestreri et al 1995; Bona
1999; Karthaus et al 2006). Early studies revealed high rates
of CVC-related thrombosis and significant reductions in
such thrombosis with antithrombotic prophylaxis compared
with no treatment (Bern et al 1990; Monreal et al 1996). In
a recent large, multinational, double blind, placebo-
controlled trial the efficacy and safety of dalteparin was
evaluated for the prevention of clinically relevant CVC-
related thrombosis in cancer patients receiving
chemotherapy via catheter (Karthaus et al 2006). This study
showed that the risk of CVC-related thrombosis was 3.7%
in dalteparin-treated versus 3.4% in the placebo-treated
patients. Not only was there no difference in risk of
thrombosis, but there was also no difference in the time to
onset of this complication between patients on dalteparin
versus placebo. The low rates of thrombosis observed in
recent studies may be a reflection of newer catheter design,
improved catheter care or a shorter period of hospitalization,
which has become common practice in the past decade.
Anticoagulation is not recommended for routine prophylaxis
of catheter related thromboembolic complications in cancer
patients (Geerts et al 2004). However, this recommendation
may change if a subgroup of cancer patients can be identified
with a higher risk for development of CVC-related
thrombosis.
Management of cancer associated
thrombosis
The goal of therapy in cancer patients with VTE is to
improve symptoms of VTE, reduce risk of recurrent VTE,
prevent pulmonary embolism, and decrease the risk of post-
thrombotic syndrome. Management of VTE in cancer
patients is problematic. Risk of recurrent thromboembolism
and of anticoagulant treatment-related bleeding should be
considered during treatment planning.
Initial treatment of thrombosis in
cancer patients
The standard regimen for treatment of VTE in cancer
patients involves the initial administration of LMWH or
UFH for approximately 1 week followed by long-term oral
anticoagulant therapy with a vitamin K antagonist, such as
warfarin, to maintain an INR of between 2.0 and 3.0. Based
on the results of several randomized controlled trials,
LMWH has replaced UFH as the initial treatment in the
majority of the patients with acute VTE. This is because
large meta-analyses of many clinical trials conducted in
inpatient and outpatient settings have revealed that LMWH
administered subcutaneously is at least as safe and effective
as UFH administered intravenously, and LMWH usually
requires no laboratory monitoring and is associated with a
reduced risk of developing heparin induced
thrombocytopenia and thrombosis, and osteoporosis (GouldVascular Health and Risk Management 2006:2(4) 354
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et al 1999; Dolovich et al 2000; van den Belt et al 2000).
LMWH is more convenient to administer than UFH because
it can be given by patients to themselves using once or twice
daily subcutaneous injection with weight-adjusted dosing
on an outpatient basis. For these reasons, LMWH has
become the drug of choice for the initial therapy for VTE.
Current guidelines from the American College of Chest
Physicians (ACCP) suggest that LMWH may also be the
treatment of choice for the long-term (for example for 3–6
months) treatment of VTE under certain circumstances such
as when vitamin K antagonists are contraindicated or
impractical, in patients with thrombosis in spite of
therapeutic levels of vitamin K antagonists and in patients
at especially high risk of recurrence. An example of the latter
would be patients with malignancy-associated VTE in whom
LMWH regimens may be more effective and safer (Buller
et al 2004).
Long-term management of thrombosis
in cancer patients
Recurrent VTE is common following the first such episode
in cancer patients. Clinical studies have shown that cancer
patients diagnosed with VTE have an increased risk of
developing recurrent thromboembolic and bleeding
complications with antithrombotic treatments, compared
with patients having VTE without cancer (Prandoni et al
2002). Problems associated with the long-term treatment of
VTE in the setting of cancer using oral anticoagulants are
related to the fact that cancer patients commonly manifest
variability in dietary intake, malnutrition, liver dysfunction
related to the presence of metastases and other factors, and
nausea and vomiting due to chemotherapy toxicity. Cancer
patients are also more likely to ingest a variety of drugs
capable of interacting with and altering the dose requirement
of oral anticoagulants. Such uncertainties might be
overcome with long-term use of LMWH. In a multicenter,
randomized clinical trial, subcutaneous therapeutic LMWH
(tinzaparin) administered for 84 days versus initial treatment
using UFH for 5 days together with long-term warfarin
sodium given to 84 days for the treatment of high risk
patients (including cancer patients) with objectively
diagnosed proximal deep-vein thrombosis were compared.
In this study, long-term tinzaparin administration was
effective compared with UFH/warfarin sodium and was
clinically and statistically significantly safer than UFH/long-
term oral anticoagulants due to a lower frequency of
hemorrhagic complications (Hull et al 2003). The results of
two randomized trials have been published comparing
LMWH versus warfarin for the prevention of recurrent VTE
in cancer patients (Meyer et al 2002; Lee et al 2003). In a
multicenter randomized trial, 3 months of treatment with
enoxaparin was compared with warfarin and a combined
outcome of bleeding plus recurrent VTE was evaluated
(Meyer et al 2002). Of the 71 evaluable patients receiving
warfarin, 15 (21%) experienced a major hemorrhage or
recurrent VTE compared with 7 (10.5%) of the 67 patients
assigned to receive enoxaparin; this difference approached
statistical significance (p=0.09). The Randomized
Comparison of Low-Molecular-Weight Heparin versus Oral
Anticoagulant Therapy for the Prevention of Recurrent
Venous Thromboembolism in Patients with Cancer (CLOT)
trial was a multicenter, randomized, open label clinical trial
that investigated whether dalteparin was more effective and
safer than oral anticoagulant therapy in preventing recurrent
thromboembolism in cancer patients who had an episode of
acute VTE (Lee et al 2003). During the six-month study
period, 27 of the 336 patients in the dalteparin group had
recurrent VTE compared with 53 of the 336 patients in the
oral-anticoagulant group (p=0.002). Thus, the probability
of recurrent VTE at six months was 17% in the oral-
anticoagulant group and 9% in the dalteparin group. No
significant difference between the dalteparin group and the
oral anticoagulant group was found in the rate of total
bleeding episodes or of major bleeding. The CLOT study
showed that dalteparin demonstrated superior safety and
efficacy compared with an oral vitamin K antagonist in for
the prevention of recurrent VTE in cancer patients.
Anticancer effect of anticoagulants
The first report of a possible beneficial effect of an
anticoagulant on the natural history of malignancy was
published in 1964 for the vitamin K antagonist, warfarin
(Michaels 1964). The first prospective randomized trial
designed to test the ability of warfarin to influence cancer
survival was published in 1981 (Zacharski et al 1981). This
study showed that survival of patients with small-cell lung
cancer (SCLC) was prolonged significantly upon the
addition of warfarin to standard combination chemotherapy
plus radiation therapy. The median survival for control
patients was 24 weeks and for warfarin-treated patients 50
weeks. Warfarin-treated patients also demonstrated a
significantly increased time to first evidence of disease
progression. Recently, several randomized trials have
examined the effect of LMWH on the survival of cancerVascular Health and Risk Management 2006:2(4) 355
Management of cancer-associated thrombosis
patients with or without VTE (Altinbas et al 2004; Kakkar
et al 2004; Klerk et al 2005; Lee et al 2005). The results of
all these clinical studies showed that LMWH provided a
survival benefit, particularly in patients in the early stages
of malignant disease. The study of Altinbas and colleagues
(2004) was well controlled and included only patients with
SCLC. However, the remaining three studies were not
controlled for tumor type, disease stage, performance status
or standard anti-tumor treatment. Thus, it remains to be
determined whether patients with tumor types other than
SCLC will respond to this treatment approach. The fact that
the coagulation mechanism is intimately involved in wound
healing and tissue remodeling and organogenesis provides
a conceptual basis for postulating that it is involved in the
disorderly growth characteristic of malignancy (Zacharski
2003). Considering the substantial number of studies in
experimental tumor systems that support the concept that
the coagulation mechanism promotes malignant growth and
the fact that numerous drugs that are relatively non-toxic
are currently available for testing, it is perhaps surprising
that more attention has not been paid to exploring this novel
cancer treatment paradigm. Further studies designed to
clarify possible anti-tumor effects of anti-thrombotic drugs,
and especially the LMWHs, and to explore the
heterogeneous pathophysiological mechanisms that pertain
to different tumor types are awaited.
Summary and future directions
LMWH is the treatment of choice for the initial treatment
of patients with VTE occurring in the setting of active
malignancy. The optimal duration of LMWH therapy for
prevention of recurrent VTE is controversial and should be
tailored to the needs of the individual patient. The advent
of new anti-thrombotic agents may provide more treatment
options in the future. However, clinical trials must be
designed carefully with full consideration given not only to
effects of treatment on VTE risk and toxicity of therapy,
but also to the possibility that agents with varying
mechanisms of action may alter the natural history of
malignancies in which that particular mechanism may drive
tumor progression. The ideal anticoagulant should have wide
therapeutic window, low risk of bleeding, no serious side
effects, and no or few drug interactions while being effective
in reducing VTE, relatively easy to administer and follow
(no laboratory monitoring), and rapidly reversible. Progress
in optimizing VTE prevention and treatment in the setting
of cancer is anticipated.
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